Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.
about
Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Primary and acquired EGFR T790 ...... pond to osimertinib treatment.
@en
Primary and acquired EGFR T790 ...... pond to osimertinib treatment.
@nl
type
label
Primary and acquired EGFR T790 ...... pond to osimertinib treatment.
@en
Primary and acquired EGFR T790 ...... pond to osimertinib treatment.
@nl
prefLabel
Primary and acquired EGFR T790 ...... pond to osimertinib treatment.
@en
Primary and acquired EGFR T790 ...... pond to osimertinib treatment.
@nl
P2093
P1433
P1476
Primary and acquired EGFR T790 ...... spond to osimertinib treatment
@en
P2093
P356
10.1016/J.CANLET.2018.03.005
P407
P50
P577
2018-03-07T00:00:00Z